Brand name: Synagis
Synagis is a medicine containing the active ingredient(s) palivizumab. On this page you will find out more about Synagis, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: palivizumab
Pack size information
Please select the pack size from the options directly below to view information on the medicine.
Information for medicine and pack size:
Synagis (1 x 100 mg vial, 1 x 1 mL inert diluent ampoule), 1 pack
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
Synagis (palivizumab) is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Safety and efficacy were established in children with bronchopulmonary dysplasia (BPD), infants with a history of prematurity (gestational age less than or equal to 35 weeks at birth) and children with haemodynamically significant congenital heart disease (CHD). (See Clinical Trials)
Table of characteristics
| Active ingredient | |
|---|---|
| Medicine schedule |
1 vial: Prescription Only Medicine, or Prescription Animal Remedy
1 diluent: Not scheduled. Not considered by committee
|
Part 1
| Visual appearance | White to off-white uniform dry cake. |
|---|---|
| Dosage Form | Injection, powder for |
| Route of administration | Intramuscular |
Part 2
| Visual appearance | Clear colourless solution. |
|---|---|
| Dosage Form | Diluent, not applicable |
| Route of administration | Intramuscular |
There is one type of pack available.
Pack type 1
| Type | Multiple containers |
|---|---|
| Storage temperature | Store at 2 to 8 degrees Celsius |
| Storage conditions | Do not Freeze,Refrigerate |
| Life time | 3 Years |
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 2 results
Synagis Powder for injection - myDr.com.au
Synagis Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Bronchiolitis - myDr.com.au
Bronchiolitis is a viral chest infection that affects mainly babies under a year old and may cause breathing difficulties, wheeze and a cough.
Read more on myDr website
Found 2 results
Palivizumab vaccine for prevention of respiratory syncytial virus infection in children with cystic fibrosis | Cochrane
Read more on Cochrane (Australasian Centre) website
Palivizumab vaccine for prevention of respiratory syncytial virus infection in children with cystic fibrosis | Cochrane
Read more on Cochrane (Australasian Centre) website
